MET and breast cancer: Recent studies reported that receptor tyrosine kinases (RTKs) such as c-Met and ALK contributed to PARPi resistance, and combined inhibition of these RTKs with PARPi induced synthetic lethality in breast cancer, liver cancer, pancreatic cancer, and ovarian cancer (28–33).